Emergent BioSolutions announces approval from FDA for CYFENDUS vaccine
Earlier known as AV7909, CYFENDUS vaccine’s efficacy for post-exposure prophylaxis is only based on studies in animal models of inhalational anthrax. Emergent senior vice president, science and development
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.